Literature DB >> 21057482

What's fueling the biotech engine-2009-2010.

Saurabh Aggarwal1.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 21057482     DOI： 10.1038/nbt1110-1165

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  15 in total

1.  Nonadherence to imatinib during an economic downturn.

Authors:  Robin K Kelley; Alan P Venook
Journal:  N Engl J Med       Date:  2010-08-05       Impact factor: 91.245

2.  Targeted cancer therapies.

Authors:  Saurabh Aggarwal
Journal:  Nat Rev Drug Discov       Date:  2010-06       Impact factor: 84.694

3.  What's fueling the biotech engine--2008.

Authors:  Saurabh Aggarwal
Journal:  Nat Biotechnol       Date:  2009-11       Impact factor: 54.908

4.  What's fueling the biotech engine?

Authors:  Saurabh Aggarwal
Journal:  Nat Biotechnol       Date:  2007-10       Impact factor: 54.908

5.  Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.

Authors:  Mark C Genovese; Jean-Claude Becker; Michael Schiff; Michael Luggen; Yvonne Sherrer; Joel Kremer; Charles Birbara; Jane Box; Kannan Natarajan; Isaac Nuamah; Tracy Li; Richard Aranda; David T Hagerty; Maxime Dougados
Journal:  N Engl J Med       Date:  2005-09-15       Impact factor: 91.245

6.  Costimulation blockade with belatacept in renal transplantation.

Authors:  Flavio Vincenti; Christian Larsen; Antoine Durrbach; Thomas Wekerle; Björn Nashan; Gilles Blancho; Philippe Lang; Josep Grinyo; Philip F Halloran; Kim Solez; David Hagerty; Elliott Levy; Wenjiong Zhou; Kannan Natarajan; Bernard Charpentier
Journal:  N Engl J Med       Date:  2005-08-25       Impact factor: 91.245

7.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Authors:  Jeffrey A Cohen; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Bhupendra O Khatri; Xavier Montalban; Jean Pelletier; Ruggero Capra; Paolo Gallo; Guillermo Izquierdo; Klaus Tiel-Wilck; Ana de Vera; James Jin; Tracy Stites; Stacy Wu; Shreeram Aradhye; Ludwig Kappos
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

8.  Treatment with monoclonal antibodies against Clostridium difficile toxins.

Authors:  Israel Lowy; Deborah C Molrine; Brett A Leav; Barbra M Blair; Roger Baxter; Dale N Gerding; Geoffrey Nichol; William D Thomas; Mark Leney; Susan Sloan; Catherine A Hay; Donna M Ambrosino
Journal:  N Engl J Med       Date:  2010-01-21       Impact factor: 91.245

9.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Authors:  John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

10.  Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.

Authors:  Jane J Kim; Sue J Goldie
Journal:  BMJ       Date:  2009-10-08
View more
  16 in total

Review 1.  Emerging technologies for making glycan-defined glycoproteins.

Authors:  Lai-Xi Wang; Joseph V Lomino
Journal:  ACS Chem Biol       Date:  2011-12-14       Impact factor: 5.100

2.  What's fueling the biotech engine--2010 to 2011.

Authors:  Saurabh Aggarwal
Journal:  Nat Biotechnol       Date:  2011-12-08       Impact factor: 54.908

3.  Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor.

Authors:  Guozhang Zou; Hirofumi Ochiai; Wei Huang; Qiang Yang; Cishan Li; Lai-Xi Wang
Journal:  J Am Chem Soc       Date:  2011-11-01       Impact factor: 15.419

4.  Site-specific chemical modification of antibody fragments using traceless cleavable linkers.

Authors:  Gonçalo J L Bernardes; Martina Steiner; Isabelle Hartmann; Dario Neri; Giulio Casi
Journal:  Nat Protoc       Date:  2013-10-03       Impact factor: 13.491

5.  A novel platform to produce human monoclonal antibodies: The next generation of therapeutic human monoclonal antibodies discovery.

Authors:  Marcus Duvall; Norma Bradley; Ryan N Fiorini
Journal:  MAbs       Date:  2011-03-01       Impact factor: 5.857

Review 6.  Bridging the gap: facilities and technologies for development of early stage therapeutic mAb candidates.

Authors:  Trent P Munro; Stephen M Mahler; Edwin P Huang; David Y Chin; Peter P Gray
Journal:  MAbs       Date:  2011-09-01       Impact factor: 5.857

7.  What's fueling the biotech engine-2011 to 2012.

Authors:  Saurabh Rob Aggarwal
Journal:  Nat Biotechnol       Date:  2012-12       Impact factor: 54.908

Review 8.  Impact of physiochemical properties on pharmacokinetics of protein therapeutics.

Authors:  Rajan Swami; Aliasgar Shahiwala
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-04-14       Impact factor: 2.441

9.  What's fueling the biotech engine-2012 to 2013.

Authors:  Rob Saurabh Aggarwal
Journal:  Nat Biotechnol       Date:  2014-01       Impact factor: 54.908

10.  Pulsatile protein release from monodisperse liquid-core microcapsules of controllable shell thickness.

Authors:  Yujie Xia; Daniel W Pack
Journal:  Pharm Res       Date:  2014-05-16       Impact factor: 4.200
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.